Myovant Sciences Ltd. (MYOV)
$26.98
$-0.01
(-0.04%)
As on 09-Mar-2023 16:01EDT
Market cap
$2,624 Mln
Revenue (TTM)
$379 Mln
P/E Ratio
--
P/B Ratio
70
Div. Yield
0 %
Quality Score
/10
Growth Score
/10
Valuation Score
/10
Momentum Score
/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-184 Mln
-
ROE
0 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-17.3
-
Debt to Equity
-0.8
-
Book Value
$--
-
EPS
$-1.9
-
Face value
--
-
Shares outstanding
97,259,504
7 Years Aggregate
CFO
$-496.88 Mln
EBITDA
$-1,187.63 Mln
Net Profit
$-1,252.01 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Myovant Sciences (MYOV)
| 0.1 | 0.3 | 0.5 | 137.1 | 37.8 | 10.9 | -- |
|
BSE Sensex*
| -8.6 | 2.9 | 1.8 | -5.1 | 6.9 | 8.1 | 11.3 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|---|---|---|---|---|---|---|
|
Myovant Sciences (MYOV)
| 73.2 | -43.6 | 78.0 | -5.4 | 29.6 | 1.6 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout Myovant Sciences (MYOV)
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the... treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Sumitovant Biopharma Ltd. Read more
-
CEO & Director
Mr. David C. Marek
-
Principal Financial Officer
Mr. Uneek Mehra
-
Headquarters
London
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Myovant Sciences (MYOV)
What is the current share price of Myovant Sciences Ltd (MYOV) Today?
The share price of Myovant Sciences Ltd (MYOV) is $26.98 (NYSE) as of 09-Mar-2023 16:01 EDT. Myovant Sciences Ltd (MYOV) has given a return of 37.85% in the last 3 years.
What is the current PB & PE ratio of Myovant Sciences Ltd (MYOV)?
Since, TTM earnings of Myovant Sciences Ltd (MYOV) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
-6.01
|
-2.62
|
|
2021
|
-7.26
|
-5.23
|
|
2020
|
-2.25
|
-6.00
|
|
2019
|
-5.85
|
369.01
|
|
2018
|
-8.91
|
33.83
|
What is the 52 Week High and Low of Myovant Sciences Ltd (MYOV)?
The 52-week high and low of Myovant Sciences Ltd (MYOV) are Rs -- and Rs -- as of 19-Jun-2026.
What is the market cap of Myovant Sciences Ltd (MYOV)?
Myovant Sciences Ltd (MYOV) has a market capitalisation of $ 2,624 Mln as on 09-Mar-2023. As per SEBI classification, it is a company.
Should I invest in Myovant Sciences Ltd (MYOV)?
Before investing in Myovant Sciences Ltd (MYOV), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.